(Q45340032)

13 December 2017

title

Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients (English)

1 reference

13 December 2017

main subject

chronic myeloid leukemia

0 references

1 reference

1

1 reference

13 December 2017

4

1 reference

13 December 2017

5

1 reference

13 December 2017

K Porkka

20

0 references

Bjørn Tore Gjertsen

7

object named as

B T Gjertsen

1 reference

13 December 2017

J Richter

2

1 reference

13 December 2017

G Barbany

3

1 reference

13 December 2017

T Gedde-Dahl

6

1 reference

13 December 2017

R Hovland

8

1 reference

13 December 2017

S Hernesniemi

9

1 reference

13 December 2017

D Josefsen

10

1 reference

13 December 2017

P Koskenvesa

11

1 reference

13 December 2017

I Dybedal

12

1 reference

13 December 2017

B Markevärn

13

1 reference

13 December 2017

T Olofsson

14

1 reference

13 December 2017

U Olsson-Strömberg

15

1 reference

13 December 2017

K Rapakko

16

1 reference

13 December 2017

S Thunberg

17

1 reference

13 December 2017

L Stenke

18

1 reference

13 December 2017

B Simonsson

19

1 reference

13 December 2017

H Hjorth-Hansen

21

1 reference

13 December 2017

Nordic CML Study Group (NCMLSG)

22

1 reference

13 December 2017

publication date

18 January 2013

1 reference

13 December 2017

1 reference

13 December 2017

volume

27

1 reference

13 December 2017

issue

7

1 reference

13 December 2017

page(s)

1520-1526

1 reference

Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia

13 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Insights into the stem cells of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Critical molecular pathways in cancer stem cells of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Chronic myelogenous leukemia stem and progenitor cells demonstrate chromosomal instability related to repeated breakage-fusion-bridge cycles mediated by increased nonhomologous end joining

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Standardized definitions of molecular response in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Low or undetectable numbers of Philadelphia chromosome-positive leukemic stem cells (Ph(+)CD34(+)CD38(neg)) in chronic myeloid leukemia patients in complete cytogenetic remission after tyrosine kinase inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Residual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric approach and predict for optimal response to imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Persistent malignant stem cells in del(5q) myelodysplasia in remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.19

21 January 2018

Identifiers

DOI

10.1038/LEU.2013.19

1 reference

Dimensions Publication ID

13 December 2017

1037478860

0 references

1 reference